UMGCC Paul Calabresi Clinical Oncology Training Program

UMGCC Paul Calabresi 临床肿瘤学培训计划

• 批准号: 8548092
• 负责人: EDWARD A. SAUSVILLE
• 金额: $ 82.69万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-05 至 2016-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8548092
• 关键词: Applications Grants; Appointment; Area; Baltimore; Cancer Center; Clinical; Clinical Oncology; Clinical Protocols; Clinical Research; Clinical Trials; Combined Modality Therapy; Commit; Dental Assistants; Development; Doctor of Medicine; Doctor of Philosophy; Educational Curriculum; Faculty; Funding; Goals; K-Series Research Career Programs; Laws; Learning; Malignant Neoplasms; Maryland; Master of Science; Mentors; Mentorship; NCI Scholars Program; Peer Review; Pharmacy facility; Population; Population Sciences; Postdoctoral Fellow; Resource Sharing; Schools; Secure; Training; Training Programs; Translational Research; Treatment-Related Cancer; Underrepresented Minority; Universities; anticancer research; base; career; career development; drug development; drug discovery; experience; medical schools; multidisciplinary; programs; success; treatment strategy

DESCRIPTION (provided by applicant): The University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC) Paul Calabresi Clinical Oncology Training Program will support career development and training of Calabresi Scholars in clinical oncology translational research. UMGCC Calabresi Scholars will have an M.D., D.O., or equivalent clinical degree, have finished clinical training, and be ready for a junior faculty appointment. In addition, Ph.D.s, Pharm.D.s, or R.N.s with a Ph.D. who have finished at least one post-doctoral experience and who are committing to a career in clinical oncology translational research are eligible. The themes to be promoted in the UMGCC Scholars Program reflect areas of UMGCC strength: multimodality treatment strategies for cancer; drug discovery and development; and clinical cancer research in underserved minority populations. The Program will provide a didactic learning experience leading to a Master of Science in Clinical Research; a clinical research experience that will focus each Scholar's development of a cancer therapy - related clinical trial to answer a hypothesis-based clinical research question with translational endpoints; and a basic/population science activity which will tie to the clinical protocol translational question. The Scholars will be assisted in these goals by each Scholar having a Mentorship Committee consisting of a Clinical Mentor, a Basic/Population Science Mentor, and a Biostatistical Mentor. In addition, an independent Grant Application Development Committee will be formed for each Scholar, unrelated to the Scholar's Mentor Committee, to promote success of the Scholar in securing independent, peer reviewed funding. The UMGCC Program is distinguished by a number of features including 1) participation and support from five professional Schools at the University of Maryland, Baltimore (UMB Schools of Medicine, Pharmacy, Nursing, Dental, and Law); 2) experienced, well-funded multidisciplinary mentors; 3) the strength of UM's existing K30 Clinical Research Curriculum for the Calabresi Scholars' didactic training; 4) close coordination and the sharing of resources with existing K12s, particularly the UM Multidisciplinary Clinical Research Career Development Award; 5) a clinical research base consisting of >150 open and accruing clinical trials reflecting multidisciplinary clinical expertise and Institutional commitment to support clinical research.

描述（由申请人提供）：马里兰大学Marlene and Stewart Greenebaum癌症中心（UMGCC） Paul Calabresi临床肿瘤学培训计划将支持Calabresi学者在临床肿瘤学转化研究方面的职业发展和培训。UMGCC Calabresi学者将拥有医学博士、医学博士或同等临床学位，已完成临床培训，并准备好担任初级教员。此外，博士学位，药学博士学位。具有博士学位、至少完成一项博士后研究并致力于临床肿瘤学转化研究的注册护士符合条件。联合海湾合作委员会学者计划将促进的主题反映了联合海湾合作委员会的优势领域：癌症的多模式治疗战略；药物发现和开发;以及在服务不足的少数群体中进行临床癌症研究。该计划将提供一个教学学习经验，导致科学的临床研究硕士学位；临床研究经验，将重点放在每个学者的癌症治疗相关临床试验的发展，以回答一个基于假设的临床研究问题与翻译终点；基础/人口科学活动将与临床方案转化问题联系起来。每位学者将有一个由临床导师、基础/人口科学导师和生物统计学导师组成的指导委员会来协助实现这些目标。此外，将为每位学者成立一个独立的资助申请发展委员会，与学者的导师委员会无关，以促进学者成功获得独立的、同行评审的资助。UMGCC项目的特色包括：1)马里兰大学巴尔的摩分校的五所专业学院（UMB医学院、药学院、护理学院、牙科学院和法学院）的参与和支持；2)经验丰富、资金充足的多学科导师；3)澳大现有的K30临床研究课程对卡拉布雷西学者的教学培训的优势；4)与现有的K12s，特别是澳大多学科临床研究职业发展奖密切协调和资源共享；5)临床研究基地，包括150个开放和累积的临床试验，反映多学科临床专业知识和机构对支持临床研究的承诺。

项目成果

Patterns of HIV viremia and viral suppression before diagnosis of non-AIDS-defining cancers in HIV-infected individuals.

HIV感染者诊断非艾滋病定义癌症之前的HIV病毒血症和病毒抑制模式。

• DOI: 10.1186/s13027-015-0033-x
• 发表时间: 2015
• 期刊: Infectious agents and cancer
• 影响因子: 3.7
• 作者: Riedel,DavidJ;Rositch,AnneF;Redfield,RobertR
• 通讯作者: Redfield,RobertR

A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma.

• DOI: 10.1177/1534735414534729
• 发表时间: 2014-09
• 期刊: Integrative cancer therapies
• 影响因子: 2.9
• 作者: Bao T;Goloubeva O;Pelser C;Porter N;Primrose J;Hester L;Sadowska M;Lapidus R;Medeiros M;Lao L;Dorsey SG;Badros AZ
• 通讯作者: Badros AZ

Outcomes and chemotherapy-related toxicity in HIV-infected patients with breast cancer.

• DOI: 10.1016/j.clbc.2013.11.002
• 发表时间: 2014-04-01
• 期刊: Clinical breast cancer
• 影响因子: 3.1
• 作者: Singh, Sukhwant N;Zhu, Yue;Riedel, David J
• 通讯作者: Riedel, David J

Chemoradiation for definitive, preoperative, or postoperative therapy of locally advanced non-small cell lung cancer.

• DOI: 10.1097/ppo.0b013e318293238d
• 发表时间: 2013-05
• 期刊: Cancer journal (Sudbury, Mass.)
• 作者: Feliciano J;Feigenberg S;Mehta M
• 通讯作者: Mehta M

High cancer-related mortality in an urban, predominantly African-American, HIV-infected population.

城市艾滋病毒感染者（主要是非洲裔美国人）的癌症相关死亡率很高。

• DOI: 10.1097/qad.0b013e32835dc068
• 发表时间: 2013
• 期刊: AIDS (London, England)
• 作者: Riedel,DavidJ;Mwangi,EvelynIvyW;Fantry,LoriE;Alexander,Carla;Hossain,MianB;Pauza,CDavid;Redfield,RobertR;Gilliam,BruceL
• 通讯作者: Gilliam,BruceL